Dutch DSM joins an EU consortium to battle ocular diseases
Heerlen - Royal DSM N.V will be the industrial partner to the Panoptes consortium, which aims to develop novel drug delivery technology for the posterior eye segment. The four year project is supported by EUR4m in funding from the Nanosciences, Nanotechnologies, Materials & New Production Technologies (NMP) Theme of the Cooperation Programme, under the 7th Research Framework Programme of the European Union. DSM will contribute the knowledge of preparing tailored amino acid- based polymers and offering use of processing facilities. The project is also a chance for DSM to validate the properties of its polyesteramide (PEA) biomaterials as a drug delivery technology. “This partnership aligns with DSM’s push for open innovation, tapping into the wider academic community to help develop breakthrough technologies to benefit patients’ clinical outcomes worldwide”, said DSM's Biomedical Research Director, Marc Hendriks. The PANOPTES consortium brings together academic experts from the University of Durham (United Kingdom), Radboud University Nijmegen (Netherlands), University of Helsinki (Finland), Complutense University of Madrid (Spain), and Eberhard Karls University Tübingen (Germany).